Tomorrow, Monday, November 16 at 15:00 CET (9:00 EST/6:00 PST), I will likely be on an ISPOR Europe Panel titled “Will COVID-19 Speed up the Adoption of Digital Well being Applied sciences? Views on Evaluating Digital Well being Applied sciences throughout International Illness Outbreaks“. The session will likely be moderated by Kristian Kidholm, PhD of the College of Southern Denmark, and my co-panelists are Hans Ossebaard, of the Nationwide Well being Care Institute (Zorginstituut Nederland) within the Netherlands and Maja Rasmussen of the College of Southern Denmark. The problem and overview are described under.
ISSUE: Digital well being applied sciences have the potential to enhance entry to care, empower sufferers and scale back prices, notably in a world confronted with the COVID-19 pandemic. It’s unclear, nevertheless, which analysis designs are finest for measuring the worth of those improvements. For prescribed drugs and different remedies, the gold commonplace is a randomized managed trial (RCT). On the planet of digital, nevertheless, RCTs’ tightly prescribed protocols, lengthy delays, and excessive value might show problematic for demonstrating real-world worth. However, with out strong proof, the worth of digital well being improvements will stay unclear. On this concern panel, panelists will present concrete examples of how the worth of digital well being improvements has been quantified by means of latest analysis, will debate the deserves of various strategies for quantifying the this worth, and focus on how COVID-19 is altering the use and valuation of digital well being applied sciences.
OVERVIEW: This panel will debate different analysis designs for measuring the worth of digital drugs and the way digital medicines are prone to evolve as extra therapy interactions are carried out remotely resulting from COVID-19. Dr. Kidholm will present a abstract of the various kinds of digital well being improvements in use in addition to an summary of some insurance policies used to incentivize elevated uptake of digital drugs. Ms. Kjær Rasmussen will describe how her analysis has used an RCT strategy to measure the worth of telemonitoring companies. Dr. Shafrin will current his analysis measuring the worth for digital drugs applied sciences—together with chip-in-pill adherence applied sciences and digital, point-of-care diagnostic exams—in circumstances the place RCT knowledge usually are not accessible. Dr. Ossebaard will current findings from a scientific literature assessment of well being know-how assessments for eHealth. Shows will likely be roughly eight minutes with 20 minutes for panel dialogue and 10 minutes for viewers questions.
Test it out!